How to Prepare a Notified Body Opinion (NBOp) for Article 117

The transition toward the new regulations under the EU Medical Device Regulation (EU MDR) emphasizes robust regulatory processes, particularly for combination products that incorporate medicinal products. Article 117 stipulates the need for a Notified Body Opinion (NBOp) for such products. This comprehensive guide aims to provide U.S.-based regulatory affairs professionals with a step-by-step approach for the preparation of a Notified Body Opinion, tailored specifically to comply with the regulatory expectations under EU MDR.

Step 1: Understanding the Framework of Article 117

Before embarking on the preparation of a Notified Body Opinion (NBOp) for Article 117, professionals must thoroughly understand the framework established by the EU MDR. Article 117 outlines the regulatory requirements applicable to medical devices that include or are used in combination with a medicinal product. This provision mandates that a Notified Body must issue an opinion on the combination product from a clinical and safety perspective.

Regulatory authorities have specified several critical components that must be included in the Notified Body’s assessment. Familiarity with these components will facilitate effective communication with the Notified Body and assist in meeting their documentation expectations. The General Safety and Performance Requirements (GSPR) as outlined in Annex II of the EU MDR must be addressed comprehensively.

• GSPR: Review each requirement outlined in Annex I closely. Ensure your clinical evaluation, risk management, and post-market surveillance plans align with GSPR.
• Interrelation of Components: Understand how the medicinal product component integrates with the medical device, including its intended use and performance characteristics.
• Notified Body Selection: Choose a competent Notified Body that is designated under the EU MDR for your device’s specific classification.

The understanding of these elements will form the basis for effective data collection and documentation. Taking the time to review and align your product characteristics with the expectations of the Notified Body is perhaps the most critical step prior to actual submission.

Step 2: Preparing the Required Documentation

The next step involves preparing the necessary documentation to support the Notified Body Opinion. The documentation should be comprehensive yet concise, directly correlating with the findings derived from the clinical evaluation, GSPR, and post-market commitments.

Specific documentation requirements may vary depending on the Notified Body, but generally will include:

• Clinical Evaluation Report (CER): A well-structured CER that confirms the safety and effectiveness of the combination product. It should cite relevant literature and possibly include clinical trial data, if available.
• Risk Management File: Ensure that your risk management process adheres to ISO 14971 standards and is reflective of both the device and the medicinal components.
• Labeling and Instructions for Use: Prepare clear and detailed labeling that narrates the use of the combination product while indicating the medicinal component.
• Post-Market Surveillance Plan: This plan must outline how the product will be monitored after it is marketed to ensure safety and performance. Emphasizing procedures to gather feedback from users and healthcare providers will be beneficial.

To provide adequate information for the Notified Body, ensure that all strands of documentation interlink, stressing their relevance to the safety requirements specified in the regulation. Furthermore, maintain concise scientific language throughout, using formal terminology that reflects the product’s efficacy and safety.

Step 3: Engaging with a Notified Body

Once documentation is ready, practitioners should establish effective communication with the selected Notified Body. This stage is critical for aligning expectations and clarifying the submission process. It is advisable to conduct a pre-submission discussion with the Notified Body to confirm the insights and data you will be submitting in the application for the NBOp under Article 117.

Diligently prepare for any preliminary questions or concerns that the Notified Body may raise. This type of engagement can facilitate a streamlined review process and increase the likelihood of approval.

• Pre-Submission Meeting: Organize a pre-submission meeting to discuss your application and address any procedural questions. It is an opportunity to understand specific safety elements that the Notified Body may focus on during their review.
• Clarification Requests: Be responsive to any requests for clarification or additional information. Timely responses show professionalism and can expedite the NBOp process.
• Documentation Layout & Submission: Adhere to specified formats and procedures for submission. Each Notified Body has its own submission guidelines which must be followed closely.

Your proactive involvement often impacts the outcomes of the review. It’s important to foster an open line of communication while maintaining professionalism throughout the interaction.

Step 4: Review Process Observations

Understanding and anticipating the review process path the Notified Body will take is essential to effectively managing the timeline and preparing for potential revisions. During the evaluation of the submitted documentation, there are several core activities undertaken by the Notified Body.

Typically, the review process includes the following stages:

• Initial Review: At this stage, the Notified Body will confirm all necessary documentation has been received and is appropriately structured. They will assess whether the submitted materials meet the requirements set forth in the EU MDR.
• Technical Evaluation: Technical evaluators will analyze technical reports, including the clinical evaluation report and risk management file, focusing on compliance with GSPR. Ensure your documentation is comprehensive enough to withstand this scrutiny.
• Expert Appeal and Consultation: The Notified Body may consult with external experts on certain complex aspects that require specialized knowledge. They may also seek input on clinical efficacy and safety data.

As the holder of the application, it is beneficial to stay engaged during the evaluation phase. Be prepared for ongoing dialogue as they may request additional data or clarification that could influence their opinion.

Step 5: Handling Feedback and Revisions

Upon completing their review, the Notified Body will produce feedback regarding the application for the NBOp. If approved, they will issue a formal opinion favorable to Article 117. However, if the opinion is unfavorable, understanding the grounds for rejection and effectively addressing concerns will be vital for a successful re-application.

Depending on the findings, you will need to:

• Addressing Nonconformities: If any findings indicate non-compliance with GSPR, undertake a thorough investigation and revision of the documentation, ensuring that all concerns are addressed.
• Resubmission Process: Understand the resubmission process for your Notified Body, ensuring all revised documents are accurately formatted and resubmitted according to protocol.
• Continuous Engagement: Maintain continuous communication with the Notified Body during this phase. This transparency often mitigates misunderstandings and aids in a smoother path to approval.

Employing a careful and systematic approach when responding helps to solidify the integrity of your product in the eyes of the Notified Body and conveys your commitment to compliance with the EU MDR guidelines.

Step 6: Post-Approval Commitments

After successfully receiving the Notified Body Opinion, certain post-approval commitments must be adhered to and monitored continuously. Maintenance of compliance with EU regulations does not cease with the issuance of approval; it is an ongoing process that encompasses several responsibilities.

• Post-Market Surveillance (PMS): Implement and regularly review your post-market surveillance plan to ensure ongoing compliance with safety standards. This should include continuous data collection from users and health care providers to assess the performance and safety of the device.
• Periodic Safety Update Reports (PSUR): When applicable, prepare and submit periodic safety update reports as dictated by regulatory authorities on the safety profile of the product, including adverse events associated with its use.
• Adaptation to Regulatory Changes: Stay informed of any changes within the regulatory landscape to ensure timely adaptation of compliance frameworks and practices.

In essence, successfully obtaining a Notified Body Opinion under Article 117 requires meticulous preparation, thorough documentation, proactive communication, and ongoing compliance management. By adhering to the steps outlined in this tutorial guide, regulatory professionals responsible for product compliance can effectively navigate the processes required to meet the requirements of the EU medical device landscape.

In conclusion, leveraging EU MDR consulting services can significantly enhance an organization’s preparedness and ability to meet regulatory compliance requirements for combination products, ensuring not only market access but also patient safety and product efficacy.

MDR Conformity Assessment Process for Device–Drug Combinations

The regulation of device–drug combinations in the European Union is governed under the Medical Device Regulation (MDR), specifically relevant to the evaluation pathways and requirements of such products. This guide serves as a comprehensive tutorial for professionals involved in ensurings compliance with the MDR, highlighting critical phases and actions necessary for successful navigation through the conformity assessment process. This US-focused guide provides actionable insights and documentation expectations to uphold both regulatory and operational excellence.

Step 1: Understand the Regulatory Framework

The first step in the MDR conformity assessment process for device–drug combinations is to thoroughly understand the regulatory framework that governs both medical devices and medicinal products. It is essential to recognize that device–drug combinations are unique entities defined under Article 117 of the EU MDR, which specifically addresses products that contain a drug component and a medical device component. Here, the nature and functionality of each component must be delineated, as it influences the regulatory pathway.

In accordance with EU MDR requirements, devices and drugs that function together to achieve a specific medical purpose must be assessed comprehensively. The first regulatory aspect to consider is the classification of the device component. Medical devices are classified into risk categories (Class I, IIa, IIb, III) based on their intended use and the potential risks involved. Understanding these classifications will help identify the appropriate notified body involvement throughout the approval process.

In the context of drug-device combinations, one must not only consider the device aspects but also the pharmacological characteristics of the medicinal component. The overall classification and assessment will largely depend on whether the primary purpose of the product is as a medicinal product or a medical device.

Documentation requirements under the MDR necessitate the submission of a quality management system detailed as per ISO 13485 standards alongside compliance with Good Manufacturing Practice (GMP) for the drug component. Thus, it is vital to familiarize oneself with the General Safety and Performance Requirements (GSPR) outlined in Annex I of the EU MDR, as these will form the basis of the conformity assessment process.

Step 2: Dossier Preparation for Notified Body Submission

Once the regulatory framework is understood, the next crucial step involves preparing the necessary documentation for submission to the notified body. Dossier preparation should align with the requirements set forth in Annex II of the MDR, which dictates comprehensive evidence of safety and efficacy, risk management plans, and clinical evaluations specific to device–drug combinations.

The essential components that should be compiled in the technical documentation include:

• Device Description: A clear and detailed structure of the device, including design specifications, manufacturing processes, and its intended use within the treatment spectrum.
• Risk Management: A thorough risk analysis must be conducted in accordance with ISO 14971, detailing the identified risks associated with the device and accompanying medicinal product.
• Clinical Evaluation: This should include literature review and clinical trial data when available, supporting the safety and performance of the device in conjunction with the drug component.
• GSPR Compliance: Document how the device meets the GSPR as stipulated in the MDR.
• Post-market Surveillance Plan: A robust strategy detailing how the continued safety and effectiveness will be monitored post-approval.

Each of these components contributes to a comprehensive dossier that will be reviewed by the notified body. Engaging in iterative feedback sessions with the notified body prior to submission can often prove beneficial as it identifies potential gaps and helps streamline the assessment process.

Step 3: Notified Body Interaction and Assessment

Following the completion and submission of the technical documentation to a relevant notified body, the next phase involves interaction and assessment by the notified body. The selection of a notified body is critical, as not all bodies are authorized to assess specific combinations; ensure that the chosen notified body has the requisite expertise in both medical devices and pharmaceuticals.

Upon submission, the notified body will conduct a thorough review of the submitted dossier, which includes assessing the compliance of the device with the MDR. This assessment process encompasses document reviews and, at times, on-site evaluations. Detailed timelines and escalation routes should be established to maintain transparent communication throughout the process.

One significant aspect of the notified body assessment is their evaluation of the clinical data provided, solidifying the necessity of a solid clinical evaluation report. This documentation must align with the Clinical Evaluation Guidelines set by the Competent Authorities. In the case of inadequacies found during the review, the notified body may issue a request for additional information or clarification which must be addressed promptly.

Throughout the assessment phase, all communications with the notified body are vital to document comprehensively. Establishing clear objectives, timelines, and feedback loops will help manage expectations and foster a collaborative relationship.

Step 4: CE Marking and Regulatory Approval

Upon successfully navigating the assessment and resolution phases with the notified body, the next step is obtaining the CE marking, which signifies compliance with EU regulations. This marking is a declaration by the manufacturer that the product meets all regulatory requirements and can be marketed within the European Economic Area (EEA).

The CE marking process involves generating the Declaration of Conformity, wherein the manufacturer formally declares that the product conforms with the applicable legislation, including all relevant aspects of the MDR. It should summarize all evaluations conducted, including risk assessments and clinical assessments. Additionally, the following actions need to be undertaken:

• Liaise with EUDAMED: Prior to marketing, registration and compliance with the European Database on Medical Devices (EUDAMED) must be ensured, so product details are uploaded for transparency and regulatory oversight.
• Maintenance of Technical Documentation: Post-CE marking, ensure that technical documentation remains continuously updated to reflect any changes made in the product’s manufacturing or intended use.
• Market Launch Strategy: Develop comprehensive marketing strategies while ensuring compliance with local regulations on advertising for combination products.

It is necessary to maintain a vigilant post-marketing surveillance strategy in compliance with the MDR’s stringent requirements. This ensures continual monitoring of the device-drug combination’s performance and safety while also fulfilling the obligations set forth in any agreed post-market commitments.

Step 5: Ongoing Compliance and Vigilance

After securing market approval through CE marking, ongoing compliance and vigilance are paramount in the lifecycle management of device–drug combinations. Continuous monitoring of product performance both in clinical and post-market settings enables proactive identification of potential issues as part of the post-market surveillance plan.

This includes:

• Periodic Safety Update Reports (PSURs): Regular reports outlining the performance and safety profile of the product should be prepared and submitted to the relevant authorities, maintaining alignment with the agreed-upon post-market surveillance strategies.
• Adverse Event Reporting: Establish mechanisms to detect and report adverse events or unsafe usage of the product that may arise during its market lifecycle. Following up on these reports is essential to address issues promptly.
• Quality Management System Updates: Inclusion of feedback and data acquired from post-market evaluations helps refine manufacturing processes and quality assurance procedures.

Lastly, it is crucial to remain informed on regulatory changes and market dynamics that may affect the compliance status of the device-drug combination. Engaging in continuous education and consultations with regulatory experts and notified bodies are essential strategies to ensure that compliance is preserved in an ever-evolving regulatory landscape.

This comprehensive tutorial provides guidance on the procedural steps for conducting a successful MDR conformity assessment process for device–drug combinations. By closely adhering to the recommended actions, companies can ensure the development of safe and effective products while maintaining compliance with both EU MDR and US regulations.

UDI Requirements for Device Components of Combination Products

The regulatory landscape for combination products in the United States, particularly concerning Unique Device Identification (UDI) requirements for device components, is complex. Understanding these requirements is vital for compliance in product development and market entry. This guide presents a systematic approach for navigating the UDI requirements under both FDA regulations and EU MDR, ensuring that regulatory affairs professionals are equipped with practical insights.

Step 1: Understanding Combination Products

Combination products are therapeutic and diagnostic products that combine drugs, devices, and/or biological products. The FDA defines a combination product as one that is comprised of a drug and a device, a drug and a biological product, or a device and a biological product. Therefore, understanding the regulatory status of each component is crucial in compliance with UDI requirements. The FDA assigns a lead center (CDER, CDRH, or CBER) based on the primary mode of action of the combination product.

The regulatory implications for combination products arise from the obligation to comply with both drug and device regulations, which can impose differing requirements. One pivotal aspect pertains to the UDI system, which was implemented by the FDA to enhance device tracing and adverse event reporting, thereby improving patient safety.

• Primary mode of action: Establish which component of the combination product is the primary mode of action, as this will determine regulatory submission pathways.
• Component classification: Ensure all components are accurately classified as drug or device based on their function and intended use.
• Labeling considerations: Keep in mind that each component may require distinct labeling, particularly with respect to UDI labeling.

Realistically, successful navigation of UDI requirements begins with a comprehensive understanding of the regulatory framework that governs combination products. Begin establishing a compliance framework that integrates UDI considerations into the product lifecycle management from the developmental stage through post-market obligations.

Step 2: Assessing UDI Requirements for Device Components

The UDI system requires that every medical device, including those within combination products, carry specific unique identifiers. This is crucial for ensuring that devices are accurately identified throughout their lifecycle. The FDA has outlined the UDI requirements in the Title 21 of the Code of Federal Regulations (CFR), section 801.20.

For device components of combination products, compliance with UDI requirements entails specific documentation. Following are critical actions to ensure compliance:

• Identify device components: Determine all device components for which a UDI is required, keeping in mind whether the devices are standalone, packaged with a drug, or part of a larger combination product.
• Select an appropriate UDI issuer: UDI numbers may be assigned through the FDA-accredited issuing agency (Interop, GS1, or HIBCC). You must select the appropriate agency to create coherent and compliant identifiers.
• Document preparation: Prepare necessary documentation including device specifications, intended use, and modes of action associated with UDI assignments. Ensure all technical documentation is meticulously organized as outlined in ISO 13485 standards.
• Establish GSPR requirements: For devices matriculating under EU regulations, comply with General Safety and Performance Requirements (GSPR), as detailed in Annex I, before proceeding with UDI requirements.

Proper identification and documentation are paramount. Engage your team early in the process to assess the impact of UDI on product development timelines and potential compliance issues.

Step 3: Preparing for Device Component UDI Submission

Once UDI for device components has been identified, the next action item is to prepare for submission. Each component must have its UDI documented in the Global UDI Database (GUDID), which is critical for tracking and post-market surveillance.

This phase requires a robust routine and accurate documentation practices to ensure that all requirements are met. Key components of the submission process include:

• Understand submission timeline: Assess how UDI submission timelines align with your product development schedule. UDI submissions must be uploaded to the GUDID prior to product launch in the U.S.
• Digital systems readiness: Ensure that your company is equipped with digital systems that can accommodate UDI information management and are integrated with EUDAMED for EU device compliance.
• Documentation of UDI attributes: Collect and prepare detailed documentation of UDI attributes, including device identifier (DI) data and production identifier (PI) information, to accurately describe the device’s life cycle, including its production, distribution, and end user.

It is crucial that your workforce is trained on UDI data requirements and database management to guarantee streamlined submission processes, reducing the likelihood of delays in product launch. Prepare for GUDID entry with checklists and timelines that include milestone laws related to your product.

Step 4: Engaging with Notified Bodies for EU Compliance

For combination products intended for the European market, engaging with Notified Bodies (NBs) is a mandatory step to ensure compliance with the EU Medical Device Regulation (MDR) and In-vitro Diagnostic Regulation (IVDR). The primary role of NBs is to conduct conformity assessments of medical devices and provide certification based on compliance with the respective EU legislation, which now includes the UDI requirements.

Engagement with NBs should be planned in advance of submitting your product to the EU market. Steps to consider include:

• Selection of Notified Body: Choose a Notified Body that is designated for the relevant device classification of your combination products. Review their scope of designation and experience with similar products.
• Pre-Submission Communication: Schedule a pre-submission meeting with the NB to clarify assessment requirements and timelines. Such communications can enhance compliance efficiency.
• Documentation for NB Review: Prepare a comprehensive technical file and ensure it aligns with the requirements specified in the relevant Annex II of the MDR, particularly paying attention to the UDI-related sections.

Engaging with Notified Bodies prior to submission facilitates transparency, making the assessment process smoother and reducing the potential for regulatory setbacks.

Step 5: Executing Post-Market Surveillance and Reporting Obligations

Once a combination product is on the market, adherence to post-market surveillance (PMS) obligations becomes imperative — especially concerning UDI requirements. The PMS framework aims to gather evidence on the clinical performance and safety of the device in the real world. This entails systematically collecting, analyzing, and reporting data derived from UDI information.

The following PMS activities are essential for maintaining compliance and organizational preparedness:

• Real-World Data Collection: Implement systems for systematically collecting real-world data on device performance, user feedback, and adverse events linked to device components.
• UDI Compliance Monitoring: Regularly review and validate the UDI information recorded in GUDID and EUDAMED to ensure consistency and accuracy.
• Reporting to Regulatory Authorities: Prepare for timely submissions of adverse events, recalls, or safety reports to the FDA and relevant European counterparts.

Incorporating PMS into the organization’s ongoing operational strategy will not only foster compliance but also raise the company’s profile as a responsible manufacturer committed to patient safety. An ongoing analysis of PMS data provides insights that may lead to product improvements and post-marketing updates, ensuring the product meets user and regulatory expectations.

Conclusion: Ensuring UDI Compliance for Combination Products

In conclusion, understanding and implementing UDI requirements for device components of combination products is a multi-faceted undertaking. From initiating documentation to engaging Notified Bodies and maintaining compliance through post-market surveillance, each step is essential in achieving regulatory success. The seamless integration of UDI compliance into product strategy not only fulfills regulatory obligations but also reinforces a commitment to patient safety and product quality.

For organizations needing support through these processes, leveraging FDA combination product consulting services could streamline compliance strategies, improve operational efficiencies, and ultimately facilitate successful product launches.

GSPR Compliance: General Safety and Performance Requirements in MDR

The European Medical Device Regulation (MDR) sets forth stringent guidelines aimed at ensuring the safety and performance of medical devices. Among these guidelines are the General Safety and Performance Requirements (GSPR), which are critical for compliance and the successful market entry of medical devices in the EU. This article provides a step-by-step tutorial focused on GSPR compliance, detailing actionable insights and documentation expectations for regulatory affairs professionals, particularly those involved in FDA combination product consulting.

Step 1: Understanding the Scope of GSPR

The GSPR under the EU MDR is found in Annex I, encompassing requirements that all medical devices and in vitro diagnostic devices must meet to demonstrate their safety and effectiveness. The purpose of GSPR is to safeguard patients while ensuring the efficacy of medical devices once they are launched on the EU market. Each requirement in GSPR pertains not only to the medical device itself but also to the intended use, the risk classification, and the lifecycle of the device.

The GSPR consists of several essential categories, including:

• General requirements: Addressing both the safety and performance of the device must be demonstrated through comprehensive clinical data.
• Design and manufacturing: Establishing quality management systems and standard operating procedures that adhere to ISO standards.
• Clinical evaluation: Ensuring systematic appraisal of a device’s performance based on clinical evidence throughout its lifecycle.
• Post-market surveillance: Highlighting the need for manufacturers to continuously monitor device performance once it is on the market.

Understanding the full scope of GSPR is the first critical step in compliance. Stakeholders must thoroughly review each requirement to determine how their specific device aligns with these obligations.

Step 2: Preparing the Device for GSPR Evaluation

Following a preliminary understanding of the GSPR, the next step involves preparing your device for evaluation. This stage lays the groundwork for product compliance and engagement with a Notified Body:

• Device Classification:

  Assign the appropriate classification to your medical device. The classification impacts the regulatory pathway and the depth of required documentation:

  • Class I: Low-risk devices; often subjected to self-certification.
  • Class IIa/IIb: Moderate to high-risk devices; require Notified Body intervention.
  • Class III: High-risk devices; necessitate rigorous review, including a full quality management system audit.

• Quality Management System (QMS):

  Ensure the establishment of a robust QMS compliant with ISO13485. This is crucial for meeting GSPR documentation requirements. Key elements of the QMS include:

  • Document control procedures.
  • Management responsibility and commitment.
  • Resource management and training programs.
  • Process validation and verification methods.

• Risk Management:

  The implementation of ISO 14971 for risk management processes is a vital step for GSPR compliance. Proper risk analysis, evaluation, control, and monitoring must be documented comprehensively.

Conducting thorough evaluations and adhering to the defined QMS protocols yields documentation that will be necessary for the subsequent GSPR evaluations.

Step 3: Conducting Clinical Evaluation as per GSPR

Under GSPR requirements, a clinical evaluation is mandatory for demonstrating device performance and safety. This evaluation must be a systematic and planned approach to collecting clinical data, and it can typically leverage existing data, peer-reviewed literature, and post-market data from similar devices:

• Clinical Evidence Requirements:

  Identify the clinical evidence necessary to demonstrate compliance with GSPR. This focuses on:

  • Direct clinical investigations.
  • Analysis of clinical literature.
  • Post-market clinical follow-up data.

• Creating a Clinical Evaluation Plan (CEP):

  Draft a comprehensive Clinical Evaluation Plan that outlines the objectives, method, timeline, and resources required for the evaluation process. Ensure that the CEP aligns with Article 61 of the MDR.

• Implementation of Clinical Evaluation:

  Carry out the clinical evaluation according to your CEP, ensuring that data collection, analysis, and reporting are completed accurately. This will necessitate collaboration across teams to ensure that insights align with overarching regulatory expectations.

Your clinical evaluation is vital, as it will be a cornerstone document that verifies your compliance with the GSPR. The results should be meticulously documented, as they contribute substantially to your device’s technical file.

Step 4: Engaging with a Notified Body for Conformity Assessment

Post Clinical Evaluation, the next phase requires engaging with a Notified Body for the conformity assessment of your device. This process is essential for compliance under the MDR:

• Selecting the Right Notified Body:

  Choose a Notified Body that is designated for your specific device classification and is authorized to assess conformity for EU MDR compliance. Factors to consider include:

  • Notified Body’s scope of designation.
  • Previous experience with similar devices.
  • The Body’s reputation and feedback from other manufacturers.

• Prepare for Notified Body Audit:

  In preparation for the Notified Body audit, compile all necessary documentation and data, including but not limited to:
  – The Technical Documentation, which should encompass the results from risk assessment, clinical evaluation, and performance data.
  – The QMS documentation outlined in accordance with ISO 13485.
  – Evidence of compliance with GSPR outlined in Annex II of the MDR.

• Conformity Assessment Process:

  The Notified Body will conduct a thorough review through an assessment process that typically includes:
  – Documentation review and evaluation of compliance.
  – On-site inspection for manufacturing practices and ISO compliance.
  – Issuance of a Declaration of Conformity upon successful assessment.

This stage is critical as the outcome determines if your device can enter the EU market successfully. It is important to document all interactions with your Notified Body meticulously, as this will aid in future audits and inspections.

Step 5: Preparing and Submitting the Technical Documentation

The Technical Documentation, often called the Technical File or Design Dossier, is crucial for demonstrating GSPR compliance and must be submitted to your Notified Body:
The structure of the Technical Documentation typically includes:

• General Device Information:

  Documentation should include device description, intended use, and classification. This gives context to the GSPR requirements and clinical evaluation data.

• Performance and Safety Data:

  Compile data supporting the device’s performance claims, including:

  • Clinical evaluation outcomes.
  • Risk management documentation.
  • Manufacturing process details, including validation and process controls.

• Quality Management System Documentation:

  Include a detailed QMS documentation that illustrates compliance with ISO 13485. This involves several management procedures, control mechanisms for supplier management, and product realization processes.

Additional components may include labeling requirements, user manuals, and a post-market surveillance plan. It is essential to ensure that your Technical Documentation is both comprehensive and transparent, as this will be reviewed extensively during the Notified Body evaluation.

Step 6: EUDAMED Registration and Post-Market Surveillance Obligations

Once the Technical Documentation has been successfully submitted and your device has received the CE mark, you must ensure that the device is registered in the European Database on Medical Devices (EUDAMED):
EUDAMED acts as a centralized repository, allowing for enhanced transparency and traceability:

• Device Registration in EUDAMED:

  Register the medical device in EUDAMED databases according to the mandated timelines following device launch to facilitate post-market surveillance activities. Registration includes:

  • Device identification information.
  • Manufacturer details.
  • Notified Body particulars.

• Post-Market Surveillance Plan:

  Establish a Post-Market Surveillance (PMS) system to continually monitor the safety and performance of your device in real-world use. Key components of the PMS include:

  • Regular collection and analysis of clinical data.
  • Field safety corrective actions in case of device incidents.
  • Periodic Safety Update Reports (PSURs) as mandated by the regulatory bodies.

• Continuous Improvement and Updates:

  Implement feedback systems that integrate findings from post-market data into future product iterations and ensure continuous improvement of the device.

Maintaining compliance with GSPR does not cease once the device is on the market. Regular updates to regulatory documentation and a proactive approach to post-market surveillance are essential to ensure ongoing compliance with EU MDR obligations.

Conclusion

In conclusion, achieving compliance with GSPR under the EU MDR regulatory framework requires thorough planning, documentation, and continuous engagement with both the Notified Bodies and regulatory bodies. By following the outlined steps—including understanding GSPR, preparing clinical evaluations, engaging with Notified Bodies, and implementing robust post-market surveillance systems—organizations can facilitate compliance and streamline market entry for their medical devices. Continuous adherence to these regulations underscores the importance of safety and effectiveness in medical devices across the EU market.

For industry stakeholders involved in FDA combination product consulting, familiarity with the EU MDR’s GSPR requirements can enhance understanding and harmonization of regulatory strategies across different regions, optimizing overall product development timelines.

EUDAMED Registration Requirements for Drug-Device Products

As the pharmaceutical and medical device landscape evolves, understanding the regulatory requirements surrounding drug-device products is essential for compliance and market access. The European Union Medical Device Regulation (EU MDR) necessitates that drug-device products are registered in the EUDAMED database. This guide provides a comprehensive, step-by-step approach to navigating the EUDAMED registration process specifically for drug-device products, aligned with the EU MDR guidelines, particularly focusing on Article 117 implications. Our aim is to assist US-based professionals in ensuring that they meet the regulatory expectations from the onset of product development through to market approval.

Step 1: Understanding the Regulatory Framework

The landscape of drug-device products is governed by both European Union regulations and guidances. The core reference is the EU MDR, which mandates a rigorous process for the registration of devices, including those that are used in conjunction with medicinal products.

Article 117 of the EU MDR is pivotal as it outlines the stipulations for Combination Products, specifically drug-device products. Understanding how this article integrates the two regulatory environments—pharmaceuticals as defined by the EU Directive 2001/83/EC and medical devices under the EU MDR—is critical. Products that fall under this category must comply with both the medicinal product requirements and the device-specific guidelines, placing a significant responsibility on manufacturers to adequately demonstrate compliance.

Furthermore, the General Safety and Performance Requirements (GSPR) indicated in Annex II of the EU MDR must also be adhered to. Drug-device products must fulfill these requirements to ensure product safety and efficacy. Therefore, a solid grasp of the regulatory framework sets the foundation for successful registration in EUDAMED.

Step 2: Preparation for EUDAMED Registration

Before proceeding to the actual registration in EUDAMED, several preparatory actions must be completed. This phase involves collating all relevant documentation, as well as ensuring that the product’s classification aligns with both EU MDR and GSPR requirements.

**1. Classify Your Product:**

• Determine whether the product is classified as a drug-device combination and identify its corresponding risk class according to the EU MDR.
• Consult Annex VIII of the EU MDR for guidance on the classification rules.

**2. Document GSPR Compliance:**

• Create documentation that clearly demonstrates how the product meets the GSPR outlined in Annex I.
• Compile risk management documentation in accordance with ISO 14971 to showcase a comprehensive understanding of potential hazards associated with the product.

**3. Engage with a Notified Body:**

• Contact an appropriate Notified Body early in the process. A Notified Body is essential for products that qualify as class IIa, IIb, or III devices.
• Prepare for the certification process as the Notified Body will require extensive documentation for product review.

By meticulously preparing these documents and confirming compliance, you will lay a strong groundwork for EUDAMED registration.

Step 3: EUDAMED Registration Process

Now that the groundwork has been established, the next step involves the actual registration process within the EUDAMED portal. This process is dictated by the EU MDR requirements and involves several sequential actions.

**1. Accessing EUDAMED:**

• To register your product, gain access to the EUDAMED database. This will typically require you to identify as a manufacturer or an authorized representative.
• Ensure your organization is registered with the EUDAMED and obtain your Single Registration Number (SRN) – a requirement for all manufacturers within the EU.

**2. Data Entry:**

• Input essential data in the Product Module of EUDAMED. This includes information on the product’s classification, intended use, compliance with GSPR, and details required as per Article 117.
• Ensure that information regarding the drug-component and the device-component is separately detailed but linked effectively to demonstrate compliance with both frameworks.

**3. Upload Supporting Documentation:**

• Attach all necessary documentation, including the declaration of conformity, clinical evaluations, and any correspondence with the Notified Body.
• Documentation must adhere to EUDAMED’s specific requirements for format and content, ensuring clarity and accessibility for reviewing authorities.

The successful completion of this submission establishes your product’s presence in EUDAMED, setting it on a pathway for regulatory approval.

Step 4: Review and Follow-up After Submission

Once the EUDAMED registration is submitted, it enters a review process where regulatory authorities will assess the registered data and documentation. Understanding the nature of this review process is imperative for efficient follow-up and potential remediation.

**1. Monitor Feedback and Requests for Additional Information:**

• After submission, be prepared to respond promptly to any queries from the regulatory authority. It is common for additional information requests to arise during the assessment period.
• Establish a communication strategy to ensure that your team can quickly address any questions or concerns raised by the authorities.

**2. Update Documentation as Necessary:**

• Should there be changes in the product’s design or intended use, ensure that EUDAMED records reflect these changes promptly.
• Regularly review your product’s documentation to maintain compliance with evolving regulations, especially if new guidance emerges post-submission.

A proactive approach during the review phase ensures smoother transitions through potential hurdles and accelerates the approval process.

Step 5: Post-Approval Commitments and Compliance Management

After obtaining approval and successful registration in EUDAMED, manufacturers are required to fulfill several post-approval commitments to ensure ongoing compliance and market surveillance.

**1. Vigilance and Reporting Obligations:**

• Implement post-market surveillance strategies to monitor product safety and performance in line with the EU MDR’s vigilance reporting requirements.
• Establish channels for reporting adverse events and incidents timely and accurately, which will necessitate an ongoing review of safety data collected from users.

**2. Periodic Regulatory Updates:**

• Stay informed of regulatory changes or guidelines that may affect your product’s compliance status. Regulations can shift, influencing the effectiveness of your previous documentation.
• Consider scheduling regular regulatory compliance audits to ensure that your documentation remains in line with the latest requirements and best practices.

Post-approval obligations are not simply a formality but a critical component of maintaining market access and goodwill with regulatory authorities, ultimately contributing to product safety and efficacy in the market.

Conclusion: The Path Ahead

Navigating EUDAMED registration for drug-device products requires careful planning, precise execution, and a deep understanding of regulatory requirements as dictated by the EU MDR. By diligently following this step-by-step guide, industry professionals can streamline the registration process, ensuring compliance with Article 117 and related EU obligations.

In conclusion, utilizing this framework as a decision-making guide can position your organization advantageously in the complex regulatory environment, particularly for drug-device products. With effective regulatory strategies, continuous monitoring of compliance status, and consultation with experts in EU MDR consulting services, organizations can achieve their commercialization goals while adhering to regulatory standards.

Labeling and IFU Requirements for Combination Devices Under MDR

Understanding the complexities surrounding the labeling and instructions for use (IFU) requirements for combination devices under the Medical Device Regulation (MDR) is critical for compliance and market access. This step-by-step guide provides a detailed approach to ensure adherence to the regulatory landscape, particularly focusing on the European Union’s MDR framework while considering pertinent guidelines for FDA combination products.

Step 1: Understand the Definition and Scope of Combination Devices

A combination device as per both the FDA and EU MDR regulations integrates a drug component with a medical device. It can take various forms, including a device that incorporates a medicinal product as an integral part, or it can be a drug delivered via a device. For regulatory purposes in the EU, these devices are governed primarily under the MDR, specifically addressing regulation on labeling and IFU requirements.

Understanding the classifications is paramount. The EU MDR categorizes products based on their risk to patients which influences their regulatory pathway and requirements. The classification leads to different expectations concerning the labeling and IFU, necessitating a clear understanding of your product’s nature and intended use.

Key actions to undertake in this step include:

• Identify the combination device type (e.g., drug-eluting stents, pre-filled syringes).
• Consult with regulatory experts to delineate between device and medicinal components.
• Review definitions provided by the European Commission regarding medical devices.

Step 2: Familiarize Yourself with Relevant Regulatory Frameworks

Understanding the relevant regulatory frameworks is crucial when preparing to meet labeling and IFU requirements. In the EU, the MDR (Regulation (EU) 2017/745) necessitates not only compliance with general safety and performance requirements (GSPRs) but also adherence to specific requirements laid out in Annex II, which deals with the technical documentation. Familiarize yourself with Article 117 of the MDR, which articulates the need for particular attention to combination products.

The FDA, through its guidelines, governs combination products using the Office of Combination Products (OCP). This office facilitates the regulatory process coordinating between the respective centers, allowing for an integrated approach. It is advisable to document which agency governs your specific combination product early in the development process to avoid regulatory pitfalls.

Key actions in this phase include:

• Review the text of the MDR and understand its implications for labeling.
• Understand the FDA’s guidelines on combination products, referencing the FDA’s Combination Products Guidance.
• Consult with legal and regulatory experts to interpret nuances in the regulatory text.

Step 3: Ensure Compliance with Specific Labeling Requirements

Labeling of combination devices under the MDR includes clear, concise, and accurate information that must be presented on the device itself and in the accompanying documentation. Significant aspects include listing the device’s name, product’s intended purpose, and essential characteristics. The label must also reflect compliance with GSPR, ensuring the device’s safety and performance at the intended use.

Additionally, the labeling must provide appropriate warnings, precautions, and instructions to ensure safe use by healthcare professionals and patients alike. The labels and accompanying IFUs must be presented in a language understood by users—typically the language of the country where the device will be marketed.

The actionable points for compliance include:

• Review GSPR in detail to ensure all aspects are covered in the labeling.
• Develop labels adhering to the design specifications outlined in the MDR, ensuring legibility and durability.
• Work closely with the Notified Body to review labeling before market submission to ensure conformance with MDR specifications.

Step 4: Develop Instructions for Use (IFU) According to Regulatory Standards

The Instructions for Use (IFU) is a critical document that accompanies combination devices. Under the MDR, the IFU must provide comprehensive details that aid users in the safe and effective utilization of the medical device. This document should include usage instructions, maintenance procedures, potential risks, and troubleshooting tips, amalgamating information for both the device and its drug component.

Creating effective IFUs necessitates an understanding of user needs and potential user errors during the device usage. It is essential to conduct usability studies to gauge how end-users interact with the device and adjust the IFU accordingly. The IFU must also highlight any incompatibilities between the drug and device components.

Key steps include:

• Gather input from end-users (healthcare providers and patients) regarding IFU usability.
• Align the content of IFU with labeling to avoid contradictions.
• Document the process of usability testing and any revisions made to the IFU pre-submission.

Step 5: Engage with Notified Bodies Early in the Preparation Process

Early engagement with a Notified Body is essential to navigate the complexities associated with combining drugs and devices. Notified Bodies are responsible for evaluating the conformity assessment of the combination device, influencing the subsequent approval and compliance measures. Establishing a collaborative relationship can streamline the review process.

During your initial consultations with the Notified Body, provide them with comprehensive documentation including your device classification, risk assessments, intended use, labeling, and IFU drafts. This engagement allows for early identification of potential issues that may arise post-submission.

Practical measures include:

• Prepare a compliance dossier that includes labeling and IFUs for preliminary review.
• Adhere to the timelines provided by the Notified Body after formal submission of your documentation.
• Maintain ongoing communication with the Notified Body to resolve any questions or clarifications that may be raised during the assessment process.

Step 6: Collect Feedback Through Market Surveillance and Post-Market Studies

Once your combination device is placed on the market, continuous monitoring and feedback collection are crucial for compliance and safety. Market surveillance not only fulfills regulatory requirements but also enhances the quality and safety of your product in real-world settings. Healthcare professionals and patients should have a mechanism to report adverse events or product complaints.

Post-market studies should be conducted to ascertain the long-term performance and safety of the combination device, contributing valuable information back to your quality management system. Feedback from these studies should be used to update labeling and IFUs as needed.

Considerations for market surveillance include:

• Develop a comprehensive plan for collecting post-market data and analyzing feedback.
• Regularly update IFUs and labels based on the feedback from market surveillance, ensuring compliance with MDR requirements.
• Document all feedback mechanisms and outcomes as part of your ongoing quality assurance commitments, maintaining compliance under EUDAMED.

Conclusion: Navigating the Regulatory Waters of Combination Devices

In conclusion, navigating the regulatory requirements for labeling and IFU for combination devices under the EU MDR necessitates a systematic approach complemented by a comprehensive understanding of both regulatory frameworks. By adhering to the outlined steps— from defining your combination devices, understanding relevant regulations, ensuring compliance with labeling standards, developing thorough instructions for use, engaging with Notified Bodies, and instituting robust post-market surveillance— manufacturers can effectively mitigate risks and foster successful market entry.

This tutorial serves as a foundational framework; however, continuous engagement with regulatory bodies and adaptation to evolving standards remain paramount to achieving sustained compliance and market success in this complex regulatory landscape.

Postmarket Clinical Follow-up (PMCF) and PMS Under MDR: A Step-by-Step Guide

In the context of the Medical Device Regulation (MDR), Postmarket Clinical Follow-up (PMCF) and Post-Market Surveillance (PMS) play pivotal roles in ensuring the safety and performance of medical devices throughout their lifecycle. This article presents a detailed step-by-step guide for professionals involved in regulatory affairs, clinical operations, quality assurance, and product teams focusing on compliance with PMCF and PMS under the MDR.

Step 1: Understanding PMCF and PMS Requirements

Before diving into PMCF and PMS activities, it’s essential to understand the frameworks established by the EU MDR, particularly Articles 83-86 that outline the responsibilities of manufacturers. PMCF refers to the continuous collection of clinical data about a device after it has been approved for market use. Its primary aim is to gather current and real-world evidence regarding the device’s performance and safety. In addition to this, PMS encompasses all the activities that an organization undertakes to monitor and assess the safety and effectiveness of a device in post-market conditions.

Legal Implications

Under the EU MDR, manufacturers are legally required to implement a post-market surveillance system (PMS) and perform PMCF activities. This includes documenting a comprehensive PMCF plan and aligning it with the clinical evaluation of the device. As detailed in Article 83, the objective is to ensure product safety and compliance with General Safety and Performance Requirements (GSPR) laid out in Annex II.

Analyzing Regulatory Guidance

Regulatory guidance documents, such as MDCG 2020-7 and MDCG 2020-3, provide clarity on PMCF activities and PMS requirements. Understanding these documents allows for a robust approach to compliance. It is critical to keep abreast of evolving regulations to ensure that PMCF and PMS strategies are aligned.

Documentation Expectations

Documentation is at the heart of PMCF and PMS activities. Companies should prepare and maintain comprehensive records covering the objectives, methodologies, and results of PMCF studies, including Post-Market Clinical Follow-up reports and PMS reports. This documentation not only supports compliance with the EU MDR but also serves as valuable evidence in the event of an audit or inspection from a Notified Body.

Step 2: Developing a PMCF Plan

The development of a PMCF plan is crucial to ensure effective post-market data collection. The plan should detail methodologies for data collection, timelines, and data analysis strategies. The design of the PMCF strategy is influenced largely by the risk classification of the medical device, its intended use, and the existing clinical data available upon market entry.

Key Components of the PMCF Plan

• Objectives: Define what information is needed to verify continued safety and effectiveness.
• Methodology: Specify study designs, such as prospective or retrospective studies, and identify the patient population.
• Data Management: Outline data collection methods (e.g., surveys, registry data) and governance practices.
• Resources: Identify necessary resources, including personnel needs and budget allocation.
• Timelines: Set clear timelines for study initiation, duration, and analysis completions.

Aligning with Stakeholder Requirements

It is also vital to engage and align your PMCF plan with the expectations of the Notified Body. This entails early discussions regarding your PMCF strategy during the regulatory submission phase, ensuring compatibility with regulatory expectations and timelines. Additionally, any studies initiated should also prepare for potential updates in EUDAMED as required.

Step 3: Conducting PMCF Studies

Execution of PMCF studies must be methodical and compliant. Commence by acquiring necessary approvals from ethics committees and ensure the study is compliant with General Data Protection Regulation (GDPR) and applicable ethical standards. A clear protocol outlining the objective, methodology, and data analysis procedures should be established and strictly adhered to during all phases of the PMCF study.

Engaging with Clinical Sites

When engaging clinical sites for PMCF studies, establish structured agreements defining responsibilities, data management, patient consent processes, and reporting mechanisms. Each site should have a designated lead who ensures adherence to the protocol and compliance with regulatory requirements.

Collecting and Analyzing Data

Pursue rigorous data collection practices to ensure reliability and validity. Monitor compliance to ensure that participant safety is prioritized and to mitigate risks throughout the study. Upon completion of data collection, conduct a thorough analysis to interpret the findings in relation to your defined objectives, utilizing appropriate statistical methodologies.

Post-Study Reporting

After the conclusion of your PMCF study, compile a comprehensive PMCF report detailing findings, methodologies, and conclusions. This report contributes significantly to your PMS documentation and can provide insight into necessary device modifications or updates to labeling and instructions for use (IFU).

Step 4: Integrating PMCF Data into PMS Activities

Once PMCF studies yield conclusive data, it’s imperative to integrate these findings into your overarching PMS framework. This holistic approach ensures that the organization continuously evaluates the safety and performance of a medical device in real-world scenarios.

Continuous Data Collection Mechanisms

Establish mechanisms for ongoing data collection even beyond PMCF studies. Engaging with users through surveys, adverse event reporting, and routine follow-up can help maintain a proactive stance on safety monitoring. It is crucial to implement a systematic method for collating and analyzing this data regularly.

Documentation of Safety and Performance

Each PMS report should document any observations from routine surveillance, including trends indicative of potential safety concerns. Document any corrective measures taken as a result of this analysis, ensuring traceability of your PMS activities. This documentation fulfills both regulatory obligations and internal quality management processes and can also be pivotal in communicating with regulatory authorities.

Periodic Safety Update Reports (PSUR)

In alignment with PMS activities, manufacturers need to generate Periodic Safety Update Reports (PSUR) that synthesize and summarize the safety issue landscape associated with a device. PSURs should be submitted to the relevant Notified Bodies and reviewed against regulatory milestones to catch any potentially adverse signs early on.

Step 5: Leveraging PMCF and PMS Insights for Continuous Improvement

The ultimate goal of PMCF and PMS is patient safety and device performance enhancement. Utilizing insights gained from these processes can provide a foundation for continuous improvement within the organization.

Feedback Loops for Product Development

Establish feedback mechanisms that allow insights gained from PMCF studies and PMS data to inform future development programs. This feedback loop should be integrated into product lifecycle management to ensure that updates and modifications consider real-world performance data.

Engagement with Regulatory Authorities

Regular interactions with regulatory authorities such as the FDA or the European Medicines Agency regarding PMCF and PMS findings can be advantageous. Open lines of communication can facilitate guidance and anticipate regulatory concerns, aligning your compliance activities appropriately with their evolving standards and expectations.

Training and Culture of Compliance

A culture of compliance is pivotal within any organization involved in regulatory activities. Regular training sessions focusing on the importance of PMCF and PMS should be implemented to ensure that all relevant personnel understand their critical roles within these frameworks. Documentation and findings should be integrated into employee training for a holistic understanding of compliance expectations.

Step 6: Preparing for Regulatory Inspections and Audits

As a closure to the PMCF and PMS processes, preparing for potential inspections and audits is fundamental. Regulatory agencies such as the FDA or Notified Bodies may request documentation related to PMCF and PMS activities. Having well-prepared files and reports can facilitate smooth audits and demonstrate a commitment to compliance.

Organizing Documentation

Ensure documentation is organized systematically and captures all PMCF and PMS activity reports, internal audits, and corrective actions taken in response to identified risks. This organization provides easy accessibility to information required during inspections and simplifies compliance demonstration to regulatory bodies.

Retention Policies

Manufacturers must have retention policies in place that define how long PMCF and PMS records should be maintained, aligning with legal requirements. As noted in the regulatory guidance, keep these documents readily available for a defined period to address any audit requests or regulatory inquiries.

Perform Mock Inspections

Regularly conduct internal mock inspections to evaluate readiness for an actual audit. This practice allows teams to identify gaps and address them promptly, moving closer to a state of audit preparedness and compliance assurance.

Conclusion

Implementing PMCF and PMS activities under the EU MDR requires a meticulous and structured approach. By understanding regulatory requirements, developing a robust PMCF plan, conducting methodical studies, and continuously integrating feedback into the organization’s culture, professionals can ensure that medical devices remain safe and effective post-approval. This detailed guide serves as a practical resource for navigating the complexities of PMCF and PMS, promoting compliance and patient safety.

Legacy Devices in Combination Products: Regulatory Path Under MDR

The regulatory landscape for legacy devices in combination products under the EU Medical Device Regulation (MDR) is complex and multifaceted. This article aims to provide a detailed, step-by-step tutorial guide for regulatory affairs professionals engaged in the development, submission, and oversight of legacy devices in combination products. Specifically, the focus will be on the obligations under the MDR, including Article 117 and the involvement of Notified Bodies, General Safety and Performance Requirements (GSPR), and other essential components. By the end of this guide, practitioners will have a clear understanding of the regulatory pathway and practical steps to ensure compliance.

Step 1: Understanding Combination Products and Legacy Devices

Before embarking on the regulatory journey, it is crucial to thoroughly understand what combination products and legacy devices are. A combination product may consist of a drug-device combination or a device-biological product combination. A legacy device, in this context, refers to a medical device that was already marketed prior to the implementation of the MDR.

According to the European Medicines Agency (EMA), the new MDR, which came into effect on May 26, 2021, significantly impacts how legacy devices are managed. The regulation stipulates that legacy devices that fall under the combination product category must comply with the new requirements, even if they were compliant before the introduction of the MDR.

In preparation for subsequent steps, stakeholders should:

• Identify whether the product qualifies as a combination product.
• Determine the classification of the device under the MDR.
• Understand the historical compliance status of the legacy device.

A comprehensive gap analysis may be beneficial to identify deviations from the new regulatory framework, clarifying which additional data and documents will be required for full compliance. This analysis will be the foundation upon which compliance strategies can be built.

Step 2: Assembling the Dossier for Regulatory Submission

The next phase involves compiling the necessary documentation for the regulatory submission. This dossier forms the core of your regulatory strategy and must align with the expectations set out by the MDR and the Notified Body involved in the review process.

The essential components of the submission dossier include:

• Technical Documentation: This must conform to Annex II of the MDR and include details such as the device description, intended use, design and manufacturing information, and risk management documentation.
• Clinical Evaluation Report (CER): For legacy devices that experience significant changes or are integrated into a combination product, a thorough clinical evaluation may be necessary.
• Post-market Surveillance Plan: Outlining how you will monitor the safety and performance of the legacy device in the post-market phase is crucial and a requirement of MDR.
• Compliance with General Safety and Performance Requirements (GSPR): A vital part of the dossier will be demonstrating how the device meets all relevant GSPR as outlined in the MDR.

Furthermore, organizations should prepare the necessary justification for how information required under Article 117 of the MDR applies to their combination product. This will involve a detailed analysis of how the drug component interacts with the device component.

It is strongly recommended to consult guidance documents provided by the Notified Body and to adopt a collaborative approach by discussing the intended strategy with them early in the process. Integrating their feedback will save time and clarify requirements.

Step 3: Engaging with Notified Bodies

Once the dossier is compiled, the next step is to engage with a Notified Body that is competent to evaluate the combination product. This interaction is critical, as the Notified Body plays an essential role in assessing conformity with the MDR.

Here are practical steps for effective engagement with Notified Bodies:

• Identify and Select a Notified Body: Verify that the Notified Body is designated for the specific type of product you are submitting. Check their scope of designation according to the official EUDAMED database.
• Pre-submission Meetings: Schedule a pre-submission meeting to discuss your dossier. This can be invaluable for obtaining insight into the Notified Body’s expectations and can help mitigate risks of non-compliance.
• Prepare the Submission Package: Compile the required documentation and submit it for review. Be prepared to respond to questions and requests for additional data promptly.

Expect the Notified Body to conduct a rigorous review process, including potential audits and on-site inspections, especially if the combination product presents novel risks or is the first of its kind within the scope of the Notified Body.

Step 4: The Review Process – What to Expect

The review process by the Notified Body is thorough and can take several months, depending on the complexity of the combination product. The aim is to ensure compliance with the requirements of the MDR and the safety and performance of the legacy device in its new role.

During the review, be prepared for the following:

• Document Requests: The Notified Body may request additional documentation or clarification of existing documents. Having an open line of communication will facilitate timely responses.
• Technical Questions: Expect inquiries regarding the clinical evaluation, risk management methodologies, and how the legacy device adheres to the latest safety standards.
• Site Audits: Be prepared for the possibility of an on-site audit of your manufacturing facility to ensure compliance with Good Manufacturing Practice (GMP) and quality management systems.

Following a comprehensive review, the Notified Body will either issue a certificate of compliance, request further information, or reject the application. It is essential to understand common pitfalls that lead to rejections, such as inadequate clinical evaluations or insufficient risk management documentation.

Step 5: Post-Approval Actions and Market Surveillance

Upon successful approval and obtaining your CE marking for the combination product, the regulatory obligations do not cease. Organizations must commit to ongoing market surveillance and compliance activities to assure continued safety and effectiveness in alignment with the MDR.

Key post-approval obligations include:

• Implementation of the Post-Market Surveillance Plan: Document and monitor the performance of the combination product, collecting data on adverse events and product performance in real-world scenarios.
• Periodic Safety Update Reports (PSUR): These must be prepared and submitted according to the risk classification of the device, as outlined in the MDR.
• Updates to Technical Documentation: Keep technical documentation and risk management files up to date with any changes in regulation, product modifications, or emerging safety data.
• Engagement with Regulatory Authorities: Establish a robust communication channel with regulatory entities and the Notified Body for any issues arising from post-market surveillance.

Moreover, the legal obligations surrounding vigilance reporting remain critical. Compliance signifies not just regulatory adherence, but also a commitment to safeguarding patient health and well-being.

Conclusion

Navigating the regulatory landscape for legacy devices in combination products can be intricate, particularly under the scrutiny of the EU MDR. By following this structured approach, regulatory affairs professionals can better manage compliance, mitigate risks, and achieve successful market entry.

To further support your compliance journey, consider leveraging the expertise provided by FDA combination product consulting services. Keeping abreast of the latest regulatory updates and guidance documents from authorities such as the EMA and Notified Bodies is equally essential for maintaining compliance in a rapidly changing environment.

CE Marking Strategy for Drug-Device Integrations

In the contemporary landscape of healthcare, the integration of drug and device modalities raises critical regulatory challenges, especially when aiming for CE Marking under the European Union Medical Device Regulation (EU MDR). This guide serves as a comprehensive walkthrough for US-based regulatory professionals looking to navigate the complexities associated with CE Marking strategies for drug-device integrations, particularly under Article 117 of the EU MDR.

Step 1: Understanding the Regulatory Framework

The regulatory landscape governing drug-device combinations is marked by numerous directives, guidelines, and regulations. To effectively guide your project towards CE Marking, it is essential to have a solid grasp of the relevant regulatory frameworks, such as the EU MDR, which came into effect on May 26, 2021. Central to these regulations is the definition of a combination product, which consists of a drug and a device intended to be used together for specific medical purposes.

Drug-device integrations may take various forms, including:

• Combination products where the device enhances the drug’s effect.
• Devices delivering a drug in a controlled manner, like prefilled syringes.
• Drugs that are considered devices in their own right due to their mode of action.

Article 117 of the EU MDR delineates the specific regulatory requirements that apply to drug-device combinations, mandating compliance with both medicinal product regulations and medical device legislation. Understanding these interplays is crucial for effective regulatory strategies.

In preparing for a CE Mark application, it is also vital to consider the implications of the General Safety and Performance Requirements (GSPR) outlined in Annex II of the EU MDR. Each requirement must be carefully addressed in the technical documentation accompanying your submission.

Lastly, familiarizing yourself with EUDAMED, the European Database on Medical Devices, will enhance your understanding of how to track regulatory milestones and requirements throughout the lifecycle of your product.

Step 2: Dossier Preparation and Documentation Expectations

Preparation of the technical dossier is a pivotal phase in the CE Marking process for drug-device integrations. This dossier should comprehensively include all necessary documentation to demonstrate compliance with both regulatory requirements outlined in the EU MDR and relevant therapeutical standards.

The first critical component of your dossier is the **Classification** of the product—this determination will influence the entire pathway you will follow. Generally, the classification is established based on the highest risk component of the product, either the drug or the device. This decision should be supported by a thorough risk assessment aligned with ISO 14971, applicable to both medical devices and pharmaceuticals.

In addressing the GSPR, it is essential to provide systematic evidence on how your product meets each requirement. This evidence may include:

• Clinical evaluation data supported by clinical studies with robust methodology.
• Non-clinical evaluation data drawn from relevant studies, including safety and biological compatibility testing.
• Technical specifications, labeling, and the manufacturing process under a quality management system consistent with ISO 13485.

Documentation should also include a comprehensive **Risk Management Plan (RMP)**. The RMP should outline identified risks, mitigation strategies, and post-market surveillance measures to ensure continuous safety monitoring post-approval. The importance of regularly updating the RMP in light of new evidence cannot be overstated.

Collaboration with a Notified Body is crucial during this stage as they may assist in evaluating conformity with the relevant directives and standards. Ensuring alignment with the Notified Body will help facilitate a smoother submission process.

Step 3: Submission to Notified Bodies

The interaction with a Notified Body marks a significant milestone in the CE Marking process. Given the complexity of drug-device integrations, choosing the right Notified Body is essential, particularly one experienced in combination products. Initiate the process by establishing clear communication with your chosen Notified Body about your product’s classification, intended use, and the specifics of the dossier you intend to submit.

Upon submission, expect an initial review where the Notified Body will assess the documentation for completeness and general compliance. Be prepared to provide additional information and clarifications as part of this iterative dialogue. Throughout this period, maintain organized documentation that includes submission forms, technical documents, clinical evaluations, and risk management frameworks.

Upon completion of the initial review phase, an assessment will follow. This phase may involve audits of manufacturing facilities and quality systems, which are crucial to ensure compliance with standards like ISO 13485. During this inspection, be ready to present evidence supporting quality protocols, production techniques, and compliance with Good Manufacturing Practices (GMP).

If the Notified Body is satisfied with the dossier, they will issue a conformity assessment. Afterward, your product will be ready for commercialization within the EU, indicated by the CE Mark affixed to the product labeling.

Step 4: Post-Market Surveillance and Compliance

Securing a CE Mark is not the end of the regulatory journey. Post-market surveillance constitutes an ongoing requirement that maintains product safety and efficacy. A robust post-marketing plan is essential, which should include both proactive and reactive plans for monitoring product performance against the expected safety standards.

Developing a comprehensive **Post-Market Surveillance Plan (PMSP)** is a regulatory commitment that lays out how you will systematically collect, analyze, and assess post-market data. Such data may include adverse event reports, user feedback, and data retrieved from registries or other sources. Regular updates to this plan should be made in response to clinical data, market changes, or regulatory amendments.

Additionally, it is vital to maintain vigilance concerning product recalls, safety alerts, and reported adverse events as outlined by relevant authorities like the FDA and EMA. Compliance with these authorities requires establishing clear routes for collecting and reporting such incidents, which can potentially influence your ongoing status and reputation within the market.

The integration of lessons learned from post-market data into product lifecycle management can also inform innovations and product enhancements. Regular audits of the compliance system, vigilance protocols, and continuous training of personnel involved in regulatory affairs should be part of periodic internal self-inspections.

Step 5: Future Regulatory Considerations and Strategic Planning

As the regulatory environment continues to evolve, it is crucial to stay informed about potential changes in legislation and best practices in the EU and US markets. Engaging in activities such as industry conferences, training sessions, and workshops can keep your organization ahead of emerging trends and regulatory expectations.

Consider the implications of new technologies and therapeutic innovations on the regulatory landscape as they arise. This includes advancements such as digital health, telemedicine, and personalized medicine, which are all gaining traction. The European Commission has also laid out the “Digital Transformation of Health and Care” strategy that can aid in navigating the regulatory requirements for products functioning within a digital ecosystem.

Furthermore, continuous collaboration with your Notified Body and engagement with regulatory agencies can enhance regulatory intelligence on upcoming guidance documents and regulatory changes. It’s particularly beneficial for regulatory teams to develop relationships with other industry stakeholders, as shared knowledge may inform strategic decision-making regarding product development and market entry.

Lastly, ensure that your quality functions align with both regulatory requirements and internal controls, enhancing compliance and operational efficiency. This alignment will provide resilience in responding to any regulatory changes or market shifts, ultimately boosting the potential for product success and sustainability in the marketplace.

EU MDR Implementation Challenges for Global Pharma Companies

The European Union Medical Device Regulation (EU MDR) has brought significant changes to the regulatory framework for medical devices, posing unique challenges for global pharmaceutical companies. Understanding and navigating these changes is essential for compliance and successful market access within the EU. This guide provides a comprehensive, step-by-step approach to address the implementation challenges of EU MDR, specifically tailored for U.S.-based companies.

Step 1: Understanding EU MDR Requirements

The first and foremost step in the EU MDR implementation process is to comprehensively understand the regulation itself. The EU MDR (Regulation (EU) 2017/745) came into effect on May 26, 2021, replacing the Medical Device Directive (MDD) and introduces new requirements concerning the marketing and oversight of medical devices. Key sections to focus on:

• General Safety and Performance Requirements (GSPR): Found in Annex I of the MDR, GSPR outlines the essential criteria that medical devices must meet to ensure safety and effective performance. A thorough understanding of these requirements is critical.
• Article 117: This article deals with the assessment of combination products that incorporate medicinal substances. It details requirements for documenting clinical evaluation and post-market surveillance.
• Notified Bodies: The EU MDR mandates that certain medical devices be assessed by designated Notified Bodies, which are responsible for the conformity assessment of devices prior to market entry. Understanding their role is essential to avoid delays.

Actions required:

• Review the regulation document in detail.
• Identify sections of the GSPR applicable to your product line.
• Consult with EU MDR experts or legal counsel specializing in the MDR to gain clarity on regulatory expectations.

Step 2: Conducting a Gap Analysis

Once a thorough understanding of the EU MDR requirements has been achieved, the next step is to conduct a gap analysis. This analysis identifies discrepancies between existing compliance documents and the new regulation standards. It serves as the foundation for your regulatory strategy moving forward.

Key components of the gap analysis include:

• Documentation Review: Assess current quality management system (QMS) documentation against the expectations set by the EU MDR. Important documents include design specifications, risk management files, and technical documentation.
• Design Control Evaluation: Evaluate if your design control processes align with MDR requirements. This includes compliance checks for verification and validation documentation.
• Risk Management Assessment: Review the risk management process to ensure it meets harmonized standards under the EU MDR, particularly ISO 14971:2019.

Actions required:

• Create a detailed checklist based on EU MDR requirements and compare with existing procedures.
• Document findings to build a roadmap for necessary updates and changes.

Step 3: Updating Technical Documentation

With the gap analysis complete, it is imperative to update technical documentation to reflect compliance with the EU MDR. Technical documentation serves as the backbone for demonstrating conformity, thus ensuring your product can be legally marketed in the EU.

The EU MDR technical documentation must include:

• Device Description: Provide comprehensive details about the device, including its intended purpose, method of operation, and any unique features.
• Risk Analysis: Conduct and document a risk analysis aligned with the EU MDR requirements, especially noting design controls and risk management processes.
• Clinical Evaluation: Update clinical evaluation reports per the requirements of Article 61. Ensure that robust clinical performance data supports the claim of safety and efficacy.

Actions required:

• Implement changes identified from the gap analysis into the technical file.
• Adopt a structured framework to ensure ongoing updates to documentation are made in response to changes in regulation or product modifications.

Step 4: Engaging Notified Bodies

Notified Bodies play a critical role under the EU MDR by conducting conformity assessment procedures for specific classes of medical devices. Engaging with a Notified Body early in the process is essential for ensuring compliance and facilitating a smoother approval process.

Effective collaboration with Notified Bodies involves:

• Selecting the Right Notified Body: Identify a Notified Body that not only covers your device classification but also has a good reputation and experience in your specific area.
• Preparation for Audits: Prepare for the Notified Body audit by ensuring all technical documentation, quality management systems, and other compliance-related materials are ready for review.
• Communication: Maintain an open line of communication with your Notified Body throughout the process. Seek their input on the interpretation of EU MDR requirements and clarity on potential hurdles.

Actions required:

• Research and select a suitable Notified Body for your product.
• Schedule initial consultations or audits to discuss your device and its compliance strategy.

Step 5: EUDAMED Registration

The European Database on Medical Devices (EUDAMED) is a key component of the EU MDR that facilitates the collection and dissemination of information on medical devices marketed in the EU. Registration and use of EUDAMED is mandatory, and it encompasses various modules for different types of information, including device registration, clinical investigations, and vigilance reporting.

Steps to ensure compliance with EUDAMED include:

• Understanding the Modules: Familiarize yourself with the different modules of EUDAMED (Registration of Devices, UDI/Devices, Clinical Investigations, Vigilance, etc.). Determine which modules apply to your devices.
• Prepare Necessary Information: Gather required data for EUDAMED registration, including Unique Device Identifier (UDI) information, device classification, and details on manufacturers and authorized representatives.
• Implementation Plan: Develop an implementation plan for ensuring data accuracy and compliance with EUDAMED requirements upon registration.

Actions required:

• Complete necessary training on EUDAMED registration requirements.
• Engage with IT teams to establish processes for data entry and ongoing compliance management.

Step 6: Post-Approval Commitments and Monitoring

Once your device has successfully navigated the approval process under the EU MDR, the need for ongoing compliance does not cease. The EU MDR emphasizes post-market surveillance (PMS) and post-market clinical follow-up (PMCF) to ensure continued safety and performance of medical devices post-approval.

Key considerations include:

• Post-Market Surveillance Plan: Develop a robust PMS plan that outlines procedures to gather and analyze data related to the performance and safety of your device. This includes reporting adverse events and implementing corrective actions when necessary.
• Maintain Vigilance Reporting: Establish protocols for vigilance reporting in accordance with Article 87 of the EU MDR. This includes serious incident reporting and field safety corrective actions.
• Periodic Safety Update Reports (PSUR): Prepare and submit PSURs as required, documenting the evaluation of benefit-risk ratios and any emerging safety information.

Actions required:

• Implement a PMS system that includes data collection from users, health professionals, and literature reviews.
• Prepare for periodic audits of your PMS processes to meet EU MDR compliance and Notified Body expectations.